2368903-18-6
Chemical Structure
FHT-1015
- CAS No.: 2368903-18-6
- Formula:C25H25N5O4S3
- Molecular Weight:555.69
IUPAC Name: (S)-N-(3-methoxy-1-oxo-1-((4-(3-(pyridin-4-yl)phenyl)thiazol-2-yl)amino)propan-2-yl)-1-(methylsulfonyl)-1H-pyrrole-3-carboxamide
InChIKey: FAYSHZVDWADZMD-NRFANRHFSA-N
SMILES: O=C(C1=CN(C=C1)S(C)(=O)=O)N[C@@H](CCSC)C(NC2=NC(C3=CC(C4=CC=NC=C4)=CC=C3)=CS2)=O
Biological Activity: FHT-1015 is a selective SMARCA4 (IC50 = 4 nM) and SMARCA2 (IC50 = 5 nM) (also known as BRG1 and BRM) inhibitor. FH-1015 is an allosteric inhibitor that causes conformation change in the BRG1/BRM protein upon interaction with an allosteric site, inhibiting ATPase activity. FH-1015 interferes with tumor cell growth and migration. FH-1015 can be studied in research for uveal melanoma and hematologic cancer[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
FHT-1015 | 98.41% | FHT-1015 is a selective SMARCA4 (IC50 = 4 nM) and SMARCA2 (IC50 = 5 nM) (also known as BRG1 and BRM) inhibitor. FH-1015 is an allosteric inhibitor that causes conformation change in the BRG1/BRM protein upon interaction with an allosteric site, inhibiting ATPase activity. FH-1015 interferes with tumor cell growth and migration. FH-1015 can be studied in research for uveal melanoma and hematologic cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Seedor, R. et al., (2021). Genetic Landscape and Emerging Therapies in Uveal Melanoma. Cancers, 13(21), 5503. [Content Brief]
- [2]. Gang Fu, et al., SMARCD1 is a dual regulator of PD-L1 expression and cell proliferation facilitating tumor evasion, Pathology - Research and Practice, Volume 270, 2025, 155975, ISSN 0344-0338. [Content Brief]
- [3]. Reichl, K. D., et al., Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors – a review of patent literature from 2019–30 June 2023. Expert Opinion on Therapeutic Patents, 34(3), 159–169. [Content Brief]
- [4]. Centore, R.C. et al. (2023) Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers.
